BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 91 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 0.93 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,356 | +169.0% | 191,527 | +167.8% | 0.12% | +132.0% |
Q2 2023 | $504 | -60.7% | 71,532 | -53.5% | 0.05% | -60.6% |
Q1 2023 | $1,282 | -99.5% | 153,718 | +703.9% | 0.13% | +296.9% |
Q3 2022 | $241,000 | -59.2% | 19,121 | -53.5% | 0.03% | -46.7% |
Q3 2021 | $591,000 | -27.6% | 41,116 | -48.7% | 0.06% | -55.6% |
Q1 2021 | $816,000 | +946.2% | 80,197 | +663.8% | 0.14% | +938.5% |
Q4 2020 | $78,000 | -58.7% | 10,500 | -73.5% | 0.01% | -87.6% |
Q2 2020 | $189,000 | -31.8% | 39,599 | -71.4% | 0.10% | +52.2% |
Q1 2020 | $277,000 | -15.8% | 138,664 | +243.4% | 0.07% | +109.1% |
Q1 2019 | $329,000 | +376.8% | 40,383 | +208.6% | 0.03% | +560.0% |
Q3 2017 | $69,000 | -84.0% | 13,086 | -63.0% | 0.01% | -83.3% |
Q4 2014 | $430,000 | -19.6% | 35,350 | -35.3% | 0.03% | +7.1% |
Q3 2014 | $535,000 | – | 54,674 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |